Elsevier

The Lancet

Volume 357, Issue 9268, 19 May 2001, Pages 1576-1582
The Lancet

Articles
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study*

https://doi.org/10.1016/S0140-6736(00)04725-5Get rights and content

Summary

Background

Interferon beta reduces activity in multiple sclerosis as measured clinically and by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the occurrence of relapses in patients after first presentation with neurological events, who are at high risk of conversion to clinically definite multiple sclerosis.

Methods

Eligible patients had had a first episode of neurological dysfunction suggesting multiple sclerosis within the previous 3 months and had strongly suggestive brain MRI findings. Patients were randomly assigned interferon beta-1a 22 μg or placebo subcutaneously once weekly for 2 years. Neurological and clinical assessments were done every 6 months and brain MRI every 12 months. Analyses excluded one patient assigned placebo who received no study injections.

Findings

241 (78%) of 308 randomised patients received study treatment for 2 years; 278 (90%) remained in the study until termination. 57 (85%) of 67 who stopped therapy did so after conversion to clinically definite multiple sclerosis. Fewer patients developed clinically definite multiple sclerosis in the interferon group than in the placebo group (52/154 [34%] vs 69/154 [45%]; p=0·047). The time at which 30% of patients had converted to clinically definite multiple sclerosis was 569 days in the interferon group and 252 in the placebo group (p=0·034). The annual relapse rates were 0·33 and 0·43 (p=0·045). The number of new T2-weighted MRI lesions and the increase in lesion burden were significantly lower with active treatment.

Interpretation

Interferon beta-1a treatment at an early stage of multiple sclerosis had significant positive effects on clinical and MRI outcomes.

Introduction

Multiple sclerosis is a severe disorder of the central nervous system. In about 85% of patients, the disease begins with a relapsing stage; the relapses are associated with perivenular foci of inflammation in the white matter. In the initial phase, relapses are generally followed by complete or almost complete clinical recovery. After this relapsing-remitting phase, most patients enter a secondary progressive phase and accumulate irreversible neurological deficits.1, 2

Treatment of patients in the early phases of the disease may be advisable for two reasons. First, studies by pathology and magnetic resonance imaging (MRI) suggest that axonal damage is an early event in multiple-sclerosis lesions and normal-appearing white matter.3, 4, 5, 6 Second, a large proportion of patients presenting with clinically isolated syndromes suggestive of demyelinating events develop new neurological symptoms leading to a diagnosis of clinically definite multiple sclerosis. In these cases, the burden of brain lesions visible on T2-weighted MRI scans is a strong predictor of conversion.7, 8, 9, 10 Interferon beta is known to reduce greatly the extent of active MRI lesions and, as a consequence, the accumulation of the MRI-measured lesion burden.11, 12, 13, 14 This treatment given early in the course of multiple sclerosis might therefore affect the subsequent course of the disease, by decreasing the amount of inflammation.15

Phase III clinical trials have shown that various formulations of interferon beta can significantly reduce clinically assessed and MRI-measured disease activity in patients with relapsing-remitting multiple sclerosis.11, 12, 13, 14 In two of these trials, the progression of disability was also decreased, albeit to a lesser extent. These studies also suggested that the beneficial effect of interferon beta in multiple sclerosis increases with drug dose and varies according to disease duration.

In a 2-year follow-up study of patients with isolated optic neuritis, treatment with high-dose intravenous methylprednisolone reduced the early risk of conversion to clinically definite multiple sclerosis.16 Although this beneficial effect seemed to be lost after 4 years,17 the findings suggest that early initiation of treatment might be important among patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

This double-blind placebo-controlled randomised study aimed to assess the effects of low-dose interferon beta-1a (Rebif, Serono, Geneva, Switzerland) on the risk of conversion to clinically definite multiple sclerosis.

Section snippets

Patients

Eligible patients had clinical syndromes indicating unifocal or multifocal involvement of the central nervous system, were aged 18–40 years, had presented with a first neurological episode suggesting multiple sclerosis in the previous 3 months, had one or more abnormalities evident during the neurological examination, and had a positive brain MRI scan. An MRI scan was judged positive when one of the following criteria was met: presence of at least four white-matter lesions on the T2-weighted

Results

375 patients were screened for the study (figure 1). 73 patients were found not to be eligible: MRI criteria were not satisfied in 21, inclusion or exclusion criteria were not satisfied in 41, eight withdrew consent, treatment could not be started in time for two, and one patient withdrew between recruitment and randomisation.

Of the 309 patients randomised, 278 (90%) completed the study. One patient in the placebo group did not receive study medication and is not included in outcome analyses.

Discussion

Pathology3, 4 and MRI studies5, 6, 26 suggest that axonal damage is an early event in the evolution of multiple sclerosis. Evidence is accumulating that, in the early phases of the disease, axonal damage depends primarily on inflammatory processes.27, 28 The mechanism of action of interferon beta in multiple sclerosis is predominantly anti-inflammatory.14 Therefore, better results would be expected with early than with later treatment of multiple sclerosis, consistent with the observed greater

References (32)

  • C Confavreux et al.

    Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

    Brain

    (1980)
  • BG Weinshenker et al.

    The natural history of multiple sclerosis: a geographically based study-1, clinical course and disability

    Brain

    (1989)
  • B Ferguson et al.

    Axonal damage in acute multiple sclerosis lesions

    Brain

    (1997)
  • BD Trapp et al.

    Axonal transection in the lesions of multiple sclerosis

    N EnglJMed

    (1998)
  • L Fu et al.

    Imaging axonal damage of normal-appearing white matter in multiple sclerosis

    Brain

    (1998)
  • G Iannucci et al.

    The prognostic value of MR and MTI findings at presentation in patients with clinically isolated syndromes suggestive of MS

    Am J Neuroradiol

    (2000)
  • M Filippi et al.

    Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

    Neurology

    (1994)
  • JI O'Riordan et al.

    The prognostic value of brain MRI in clinically isolated syndromes of the CNS:a 10–year follow-up

    Brain

    (1998)
  • F Barkhof et al.

    Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

    Brain

    (1997)
  • PA Brex et al.

    Detection of ventricular enlargement in patients at the earliest clinical stage of MS

    Neurology

    (2000)
  • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I, clinical results of a multicenter, randomized, double-blind, placebo-controlled trial

    Neurology

    (1993)
  • LD Jacobs et al.

    Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

    Ann Neurol

    (1996)
  • Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis

    Lancet

    (1998)
  • Evidence of interferon b-1a dose response in relapsing-remitting MS

    Neurology

    (1999)
  • VW Yong et al.

    Interferon beta in the treatment of multiple sclerosis: mechanisms of action

    Neurology

    (1998)
  • RW Beck et al.

    A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis Study Group

    N Engl J Med

    (1992)
  • Cited by (0)

    *

    Other members listed at end of paper

    View full text